NL-OMON33939尚未招募不适用
An open-label, parallel group study to explore the pharmacokinetics of eribulin (E7389) in patients with advanced solid tumors and normal or reduced hepatic function according to the Child Pugh system. - NVT
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- Eisai
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •General Inclusion Criteria for all Groups
- •1. Patients must have a histologically or cytologically confirmed advanced solid tumor that has progressed following standard therapy or for which no standard therapy exists (including surgery or radiation therapy)
- •2. Age >= 18 years
- •3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- •4. Life expectancy of >= 3 months
- •5. Adequate renal function as evidenced by serum creatinine <= 2.0 mg/dL (176 µmol/L) or calculated creatinine clearance >= 40 mL/minute (min) per the Cockcroft and Gault formula
- •6. Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) >= 1.5 x 109/L, hemoglobin >= 10.0 g/dL (>= 6.2 mmol/L) (a hemoglobin < 10.0 g/dL (< 6.2 mmol/L) is acceptable if it is corrected by growth factor or transfusion), and platelet count >= 100 x 109/L
- •7. Patients willing and able to comply with the study protocol for the duration of the study
- •8. Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice
- •Additional Inclusion Criteria for the Group of Patients with No Hepatic Impairment
- •Patients must meet all the general inclusion criteria listed above plus have:
- •Normal hepatic function as evidenced by: International Normalized Ratio (INR), albumin, bilirubin, alanine transaminase (ALT) and aspartate transaminase (AST) within the institution*s normal laboratory ranges and alkaline phosphatase (ALP) <= 2.5 times the upper limit of normal range (ULN) and with no clinical signs of ascites.
- •Additional Inclusion Criteria for the Group of Patients with a History of Known Hepatic Impairment
- •Patients must meet all the general inclusion criteria listed above plus have either:
- •Mild hepatic dysfunction (Child-Pugh A) according to the Child-Pugh scoring system criteria, where patients with laboratory values within normal ranges will not be included in the Child-Pugh A category
- •Or, Moderate hepatic dysfunction (Child-Pugh B) according to the Child-Pugh scoring system criteria
排除标准
- •Exclusion Criteria
- •1. Patients who have received any of the following treatments within the specified period before eribulin mesylate (E7389) treatment start:
- •a Chemotherapy, radiation, biological therapy within 3 weeks
- •b Hormonal therapy within 1 week
- •c Any investigational drug within 4 weeks
- •2. Patients with any clinically significant laboratory abnormality except for those parameters influenced by hepatic impairment.
- •3. Patients with severe (Child-Pugh C) hepatic dysfunction according to the Child-Pugh scoring system
- •4. Patients with encephalopathy >= grade 1
- •5. Patients receiving any drug known to induce or inhibit CYP3A4 activity.
- •6. Patients, who require therapeutic anti-coagulant therapy other than for line patency with warfarin or related compounds and cannot be changed to heparin-based therapy, are not eligible
- •7. Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
- •8. Fertile men who are not willing to use contraception or fertile men with a female partner who are not willing to use contraception
- •9. Severe/uncontrolled intercurrent illness/infection
- •10. Significant cardiovascular impairment (history of congestive heart failure > NYHA grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia)
- •11. Patients with organ allografts requiring immunosuppression (not including blood and blood components transfusions)
- •12. Patients with known positive HIV status
- •13. Patients with brain or subdural metastases are not eligible, unless they are stable and have completed local therapy and have discontinued the use of corticosteroids for this indication for at least four weeks before starting treatment with eribulin mesylate (E7389).
- •14. Patients with meningeal carcinomatosis
- •15. Patients with a hypersensitivity to halichondrin B and/or halichondrin B-like compounds
- •16. Patients who participated in a prior E7389 clinical trial
- •17. Patients with preexisting neuropathy > G2
- •18. Patients with other significant disease or disorders that, in the Investigator*s opinion, would exclude the patient from the study
研究者
相似试验
招募中
2 期
Efficacy of anti-VEGF drug on retinopathy of prematurityRetinopathy of prematurityretinopathy of prematurityJPRN-jRCTs051210204eda Kaori34
进行中（未招募）
不适用
Pharmacokinetics and Safety of Doripenem in hospitalized Pediatric Patients from 3 Months to 17 Years of AgeEUCTR2011-005159-15-Outside-EU/EEAJohnson & Johnson Pharmaceutical Research & Development, L.L.C.50
进行中（未招募）
不适用
A Open-Label, Parallel-Group, Exploratory Study to Evaluate the Efficacy and Safety of 400 µg Regadenoson Bolus for Pharmacological Stress EchocardiographySuspected coronary artery diseaseMedDRA version: 9.1Level: LLTClassification code 10011078Term: Coronary artery diseaseEUCTR2008-003839-20-GBGilead Sciences, Inc.
已完成
不适用
An open label, crossover study to investigate the safety and tolerability of Sifrol® (pramipexole) (Boehringer Ingelheim) prolonged release tablets in order to establish the maximum tolerable dose and to assess bioequivalence of Pramipexole prolonged release tablets (Synthon B.V.) compared to Sifrol® prolonged release tablets (Boehringer Ingelheim) in healthy subjects in steady-state conditions10042258parkinson's diseaseNL-OMON36833Synthon B.V52
已完成
不适用
A randomized, open-label, parallel group study to evaluate the efficacy and safety of the oral administration of Bifidobacterium animalis subsp. lactis LKM512 in patients with atopic dermatitisAtopic dermatitisJPRN-UMIN000005695Kyodo Milk Industry Co. Ltd.50